Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04596150
Title Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors CytomX Therapeutics

triple-receptor negative breast cancer

Her2-receptor negative breast cancer



CX-072 + CX-2009

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.